Vistagen Therapeutics Inc <VTGN.OQ> expected to post a loss of 51 cents a share - Earnings Preview
Vistagen Therapeutics Inc VTGN.OQ VTGN.O is expected to show a fall in quarterly revenue when it reports results on February 13 for the period ending December 31 2024
The South San Francisco California-based company is expected to report a 56.2% decrease in revenue to $180 thousand from $411.4 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vistagen Therapeutics Inc is for a loss of 51 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $12.00, above its last closing price of $2.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.39 | -0.39 | -0.42 | Missed | -7.7 |
Jun. 30 2024 | -0.41 | -0.40 | -0.35 | Beat | 13.6 |
Mar. 31 2024 | -0.33 | -0.36 | -0.25 | Beat | 31 |
Dec. 31 2023 | -0.28 | -0.30 | -0.22 | Beat | 27.3 |
Sep. 30 2023 | -0.68 | -0.68 | -0.66 | Beat | 2.9 |
| |||||
Mar. 31 2023 | -1.50 | -1.75 | Missed | -16.7 | |
Dec. 31 2022 | -2.40 | -2.10 | -1.50 | Beat | 28.6 |
This summary was machine generated February 7 at 11:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Eurozone July HICP Commentary: The Euro to Enter a Fluctuation Range
TradingKey - On 20 August 2025, the eurozone released the Harmonised Index of Consumer Prices (HICP) data for July. In line with the general market expectations, the headline HICP remained unchanged month-on-month, while the core HICP fell into negative territory
FOMC August Meeting Minutes Commentary: Diverging Opinions, Rate Cut Optimism Outweighs Concerns, Your U.S. Stock Portfolio Remains Secure
TradingKey - On 21 August 2025, the Federal Open Market Committee (FOMC) released its latest meeting minutes, which revealed divisions among Fed officials due to a weakening job market and the impact of tariffs on inflation.
Fed at a Crossroads: Powell Faces the Spotlight at Jackson Hole in a Moment of Fed Uncertainty
TradingKey - The annual Jackson Hole Symposium is currently underway, with Federal Reserve Chair Jerome Powell’s speech on Friday, August 22, drawing global attention. Amid growing internal divisions within the Fed and external pressure from the Trump administration to reshape its leadership, will
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed Chair
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...
